Melatonin and Risk Of Cardiovascular Events And Malignant Tumors In The Elderly
Melatonin and Risk Of Cardiovascular Events And Malignant Tumors In The Elderly
Cardiovascular diseases and tumors seriously threaten human health. There are many risk
 factors that affect the occurrence and death of cardiovascular diseases and malignant tumors.
 In addition to genetic and congenital factors, it also includes bad lifestyles, such as
 smoking, drinking, abnormal metabolism, excessive stress, etc. Many factors such as excessive
 stress and staying up late can cause abnormal circadian rhythms. The regulation of circadian
 rhythm is likely to be a key key to the early prevention of cardiovascular diseases and
 tumors.

 Melatonin has an important role in regulating the circadian rhythm of the human body. The
 latest research of our research group confirmed that melatonin can reduce the level of
 oxidative stress through the retinoic acid-related orphan nuclear receptor alpha (RORα) and
 thereby inhibit pathological cardiac hypertrophy; melatonin can regulate the polarization and
 polarization of macrophages RORα receptor stabilizes vulnerable plaque in arteries and
 prevents plaque rupture.

 In China, melatonin is widely used in the market as a health product. However, the protective
 mechanism of melatonin in cardiovascular diseases and tumors is still unclear, and
 large-scale population intervention studies are still lacking. The level of melatonin in the
 daytime changes little with age, but the peak at night gradually decreases with age. In
 people aged 60 and above, the peak of melatonin at night decreased significantly. We
 speculate that melatonin supplementation may be able to reduce the oxidative damage of
 mitochondria by maintaining the level of melatonin at night in the body, delay cell decay,
 and delay this physiological process.

 Therefore, the project team intends to combine the developed new cardiovascular disease and
 tumor risk prediction models in the Shanghai elderly cohort established in the early stage,
 and randomize groups of healthy people in the same risk stratification, according to whether
 or not to supplement melatonin. There are two cohorts: the melatonin intervention cohort and
 the parallel control cohort. By observing the efficacy indicators of cardiovascular disease
 and tumor incidence in the two groups during the follow-up period, it provides evidence-based
 medical evidence for the future clinical application of melatonin.
Cardiovascular diseases and tumors seriously threaten human health. With the aging of the
 population in my country, the number of patients with two diseases has been increasing year
 by year, the difficulty of treatment has greatly increased, and the prognosis of most
 patients is poor. Therefore, it is of great clinical significance to explore safe and
 effective intervention programs to prevent cardiovascular diseases and malignant tumors in
 the elderly.

 There are many risk factors that affect the occurrence and death of cardiovascular diseases
 and malignant tumors. In addition to genetic and congenital factors, it also includes bad
 lifestyles, such as smoking, drinking, abnormal metabolism, excessive stress, etc. Many
 factors such as excessive stress and staying up late can cause abnormal circadian rhythms [5,
 6]. The regulation of circadian rhythm is likely to be a key key to the early prevention of
 cardiovascular diseases and tumors.

 Melatonin has an important role in regulating the circadian rhythm of the human body. A
 number of basic and clinical studies at home and abroad have shown that melatonin has a
 protective effect on inhibiting cardiovascular disease and tumor occurrence. The latest
 research of our research group confirmed that melatonin can reduce the level of oxidative
 stress through the retinoic acid-related orphan nuclear receptor alpha (RORα) and thereby
 inhibit pathological cardiac hypertrophy; melatonin can regulate the polarization and
 polarization of macrophages RORα receptor stabilizes vulnerable plaque in arteries and
 prevents plaque rupture.

 In China, melatonin is widely used in the market as a health product. Melatonin has a wide
 range of sources, no obvious toxic and side effects to the body, and high bioavailability,
 which suggests that it can prevent cardiovascular diseases and It has important potential in
 the occurrence of tumors. However, the protective mechanism of melatonin in cardiovascular
 diseases and tumors is still unclear, and large-scale population intervention studies are
 still lacking. The level of melatonin in the daytime changes little with age, but the peak at
 night gradually decreases with age. In people aged 60 and above, the peak of melatonin at
 night decreased significantly. We speculate that melatonin supplementation may be able to
 reduce the oxidative damage of mitochondria by maintaining the level of melatonin at night in
 the body, delay cell decay, and delay this physiological process.

 Therefore, the project team intends to combine the developed new cardiovascular disease and
 tumor risk prediction models in the Shanghai elderly cohort established in the early stage,
 and randomize groups of healthy people in the same risk stratification, according to whether
 or not to supplement melatonin. There are two cohorts: the melatonin intervention cohort and
 the parallel control cohort. By observing the efficacy indicators of cardiovascular disease
 and tumor incidence in the two groups during the follow-up period, it provides evidence-based
 medical evidence for the future clinical application of melatonin.
Inclusion Criteria:

 1. Queue members;

 2. Han nationality;

 3. Between 60-74 years old, no gender limit;

 4. Women are in menopause;

 5. Patients without a history of malignant tumors (except for non-melanoma skin cancer),
 myocardial infarction, stroke, transient ischemic attack (TIA), angina, coronary
 artery bypass graft (CABG) or Percutaneous Coronary Intervention;

 6. No mental illness;

 7. No history of supplement allergy or supplement allergy;

 8. Subjects voluntarily participate in this study, sign an informed consent form, have
 good compliance, and cooperate with follow-up.

 Exclusion Criteria:

 1. People who have difficulty swallowing or have known supplementary malabsorption;

 2. Have received any other clinical trial treatment within 1 year;

 3. The subject has a known, active or suspicious autoimmune disease;

 4. The subject has severe infections, including but not limited to infections requiring
 hospitalization, bacteremia, severe pneumonia, etc.;

 5. The subject has used a live attenuated vaccine in the past 30 days;

 6. The subject has been taking antidepressant medication before or is taking;

 7. Use of anticoagulants at baseline, history of kidney stones, renal failure or
 dialysis, hypercalcemia, hypoparathyroidism or hyperthyroidism, severe liver disease
 (cirrhosis), sarcoidosis or other granulomatous diseases, such as Active chronic
 tuberculosis or Wegener's granulomatosis, dementia, epilepsy, rheumatoid arthritis,
 sleep apnea syndrome, alcoholism;

 8. Situations deemed unsuitable by other researchers.